Search Results | Blood | American Society of Hematology

1-20 of 50

2 3

Sort by

Sort Order Select

Journal Articles

Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

Wangjun Cao, Lin He, Hong Zheng, MDPhD, Xiaobing Huang, Xi Yang, Xiaodong WANG, MD, Jingying Dai, PhD

Blood (2020) 136 (Supplement 1): 53–54.

DOI: https://doi.org/10.1182/blood-2020-138462

Published: 2020

Journal Articles

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Yue Wei, PhD, Hong Zheng, Naran Bao, Rashmi Kanagal-Shamanna, MD, Caleb Class, PhD, Hui Yang, PhDMD, Guillermo Montalban Bravo, MD, Irene Ganan-Gomez, PhD, Kelly Soltysiak, PhD, Kim-Ann Do, Simona Colla, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 562.

DOI: https://doi.org/10.1182/blood-2019-122574

Published: 2019

Journal Articles

Graft-Versus-Host Disease Causes the Failure of Donor Hematopoietic Progenitor Cells to Reconstitute Plasmacytoid Dendritic Cells That Promote Tolerance of Donor T Cells Against the Host

Yuanyuan Tian, Lijun Meng, PhD, Hongshuang Yu, Ying Wang, PhD, Tien Bui, Shin Mineishi, MD, Hong Zheng, MD PhD, Stefania Gallucci, MD, Yanyun Zhang, Shaoyan Hu, MD PhD, Yi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 193.

DOI: https://doi.org/10.1182/blood-2019-128721

Published: 2019

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

DOI: https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

DOI: https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Christopher J Pizzola, MD MPH, Kevin L Rakszawski, MD, W. Christopher Ehmann, MD, Witold B. Rybka, MD, Baldeep Wirk, MD, Seema Naik, MD, Hong Zheng, MD PhD, Brook Silar, Gina Mackey, CCRP, Shin Mineishi, MD, Kentaro Minagawa, MD PhD, David F. Claxton, MD

Blood (2019) 134 (Supplement_1): 5724.

DOI: https://doi.org/10.1182/blood-2019-128817

Published: 2019

Journal Articles

Efficacy and Safety Evaluation of Elderly Patients with AML Based on Clinical Common Chemotherapy Regimens Under Real-World Events

Yu Wang, Mengying Zou, Xi Yang, Li Hui, Hong Zheng, MD PhD

Blood (2019) 134 (Supplement_1): 5109.

DOI: https://doi.org/10.1182/blood-2019-128608

Published: 2019

Journal Articles

The Increase on Th1 and CD8+T Levels While a Decrease on Treg Level after Dasatinib Treatment Indicate a Better Therapeutic Response to Dasatinib and Deeper Clinical Remission in Chronic Myelogenous Leukemia Patients

Jingying Dai, PhD, Hong Zheng, MD PhD, Xiaobing Huang, Xi Yang, Xiaodong WANG, MD

Blood (2019) 134 (Supplement_1): 5376.

DOI: https://doi.org/10.1182/blood-2019-128413

Published: 2019

Journal Articles

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Chenglong Li, MDand PhD, Xi Yang, Jingying Dai, PhD, Ningning Tang, Hong Zheng, MD PhD, Chunsen Wang, MD, Xiaobing Huang

Blood (2019) 134 (Supplement_1): 1966.

DOI: https://doi.org/10.1182/blood-2019-126632

Published: 2019

Journal Articles

Long-Term Follow-up of Hematopoietic Stem Cell Transplantation with the Modified Peking Regimen for the Treatment of Acute Leukemia

Xi Yang, Chenglong Li, MDand PhD, Rong Zhang, MDand PhD, Hong Zheng, MD PhD, Qing Wei, MD PhD, Chunsen Wang, MD, Jingying Dai, PhD, Xiaobing Huang, Ningning Tang

Blood (2019) 134 (Supplement_1): 2034.

DOI: https://doi.org/10.1182/blood-2019-124419

Published: 2019

Journal Articles

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Chenchen Zhao, MD, Bei Jia, MD PhD, Liru Wang, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 1526.

DOI: https://doi.org/10.1182/blood-2018-99-113547

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

DOI: https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

Journal Articles

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Bei Jia, MD PhD, Chenchen Zhao, MD, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 5250.

DOI: https://doi.org/10.1182/blood-2018-99-113578

Published: 2018

Journal Articles

Prognostic Value of Epstein-Barr Virus (EBV)-Induced Gene 3 (EBI3) in Diffuse Large B Cell Lymphoma

Hong Zheng, MD PhD, Juan Huang, MD

Blood (2018) 132 (Supplement 1): 5411.

DOI: https://doi.org/10.1182/blood-2018-99-117970

Published: 2018

Journal Articles

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Jingying Dai, PhD, Xi Yang, Xiaobing Huang, Hong Zheng, MD PhD, Xiaodong Wang, MD

Blood (2018) 132 (Supplement 1): 4272.

DOI: https://doi.org/10.1182/blood-2018-99-113032

Published: 2018

Journal Articles

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

Xi Yang, Hong Zheng, MD PhD, Jingying Dai, PhD, Chenglong Li, MDand PhD, Rong Zhang, MD PhD, Xiaodong WANG, MD, Chunsen Wang, MD, Xiaobing Huang

Blood (2018) 132 (Supplement 1): 3424.

DOI: https://doi.org/10.1182/blood-2018-99-111671

Published: 2018

Journal Articles

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

Bei Jia, MD PhD, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Liru Wang, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 108.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.108.108

Published: 2017

Journal Articles

This Is a Title in Chidamide, a Novel HDAC Inhibitor, Is Effective for Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation and Results in Th1 Polarization in AML Patients with AML1-ETO

Xi Yang, Xiaobing Huang, MDand PhD, Hong Zheng, MDPhD, Chenglong Li, MDand PhD, Jingying Dai, PhD, Rong Zhang, MDand PhD, Xiaodong Wang, PhD, Chunsen Wang, MD

Blood (2017) 130 (Supplement 1): 3278.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3278.3278

Published: 2017

Journal Articles

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Bei Jia, MD PhD, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, MDPhD

Blood (2017) 130 (Supplement 1): 3946.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3946.3946

Published: 2017

Journal Articles

Mechanisms of GVL-Resistance: T Cell Exhaustion and a Failure of Antigen Cross-Presentation

Meng Zhou, Sarah Rosenberger, Kai Zhao, PhD, Hong Zheng, MDPhD, Warren D Shlomchik, MD

Blood (2017) 130 (Supplement 1): 4461.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4461.4461

Published: 2017

2 3

NARROW

Dasatinib Promotes the Maturation of Healthy Donors and Chronic Myelogenous Leukemia Patients Derived Dendritic Cells

KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice

Graft-Versus-Host Disease Causes the Failure of Donor Hematopoietic Progenitor Cells to Reconstitute Plasmacytoid Dendritic Cells That Promote Tolerance of Donor T Cells Against the Host

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Efficacy and Safety Evaluation of Elderly Patients with AML Based on Clinical Common Chemotherapy Regimens Under Real-World Events

The Increase on Th1 and CD8+T Levels While a Decrease on Treg Level after Dasatinib Treatment Indicate a Better Therapeutic Response to Dasatinib and Deeper Clinical Remission in Chronic Myelogenous Leukemia Patients

Dose-Adjusted Granulocyte Colony-Stimulating Factor Plus Dexamethasone Achieves More CD34+ Cell Mobilization and Earlier Engraftment in Haploidentical Hematopoietic Stem Cell Transplantation

Long-Term Follow-up of Hematopoietic Stem Cell Transplantation with the Modified Peking Regimen for the Treatment of Acute Leukemia

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Prognostic Value of Epstein-Barr Virus (EBV)-Induced Gene 3 (EBI3) in Diffuse Large B Cell Lymphoma

Dasatinib Significantly Enhances the Level of Th1 Cells While Decreases the Level of Treg Cells in Chronic Myeloid Leukemia Patients, and Th1 Can be a Potential Marker for Evaluating the Therapeutic Efficacy and Prognosis

Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients

Eomes + T-bet int CD8 T Cells Are Functionally Impaired and Associate with Primary Refractory Disease in Patients with Acute Myeloid Leukemia (AML)

This Is a Title in Chidamide, a Novel HDAC Inhibitor, Is Effective for Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation and Results in Th1 Polarization in AML Patients with AML1-ETO

Bone Marrow CD8 T Cells Express High Frequency of PD-1 and Exhibit Reduced Anti-Leukemia Response in AML Patients

Mechanisms of GVL-Resistance: T Cell Exhaustion and a Failure of Antigen Cross-Presentation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only